Technical Analysis for KRTX - Karuna Therapeutics, Inc.

Grade Last Price % Change Price Change
A 329.83 0.03% 0.09
KRTX closed up 0.03 percent on Friday, March 15, 2024, on 2.44 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 53.27%
180 Bullish Setup Bullish Swing Setup 53.27%
NR7 Range Contraction 53.27%
Slingshot Bullish Bullish Swing Setup 56.04%
Overbought Stochastic Strength 56.04%
NR7 Range Contraction 50.58%
Doji - Bearish? Reversal 50.58%
Gapped Up Strength 50.58%
Overbought Stochastic Strength 50.58%
Stochastic Sell Signal Bearish 52.70%

   Recent Intraday Alerts

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Karuna Therapeutics, Inc. Description

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Alzheimer's Disease Schizophrenia Central Nervous System Disorders Nervous System Disorders Psychosis Treatment Of Central Nervous System Disorders Puretech Health

Is KRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 329.99
52 Week Low 158.375
Average Volume 765,183
200-Day Moving Average 228.31
50-Day Moving Average 317.38
20-Day Moving Average 319.40
10-Day Moving Average 321.59
Average True Range 3.32
RSI (14) 75.43
ADX 33.43
+DI 31.89
-DI 21.73
Chandelier Exit (Long, 3 ATRs) 320.04
Chandelier Exit (Short, 3 ATRs) 306.01
Upper Bollinger Bands 327.48
Lower Bollinger Band 311.31
Percent B (%b) 1.15
BandWidth 5.06
MACD Line 3.83
MACD Signal Line 3.22
MACD Histogram 0.6037
Fundamentals Value
Market Cap 12.57 Billion
Num Shares 38.1 Million
EPS -10.94
Price-to-Earnings (P/E) Ratio -30.15
Price-to-Sales 2037.84
Price-to-Book 9.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 330.19
Resistance 3 (R3) 330.20 330.10 330.13
Resistance 2 (R2) 330.10 330.00 330.09 330.11
Resistance 1 (R1) 329.96 329.95 330.03 329.95 330.09
Pivot Point 329.86 329.86 329.89 329.85 329.86
Support 1 (S1) 329.72 329.76 329.79 329.71 329.57
Support 2 (S2) 329.62 329.71 329.61 329.55
Support 3 (S3) 329.48 329.62 329.53
Support 4 (S4) 329.47